Pulmonologists and PCPs reveal a positive outlook for triple combination therapies.
By Christina Vasiliou, Senior Analyst
28 March 2016
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
Pulmonologists and primary care physicians eagerly anticipate the approval of triple combination therapies as they will simplify the management of COPD for patients with advanced diseases who require treatment with multiple inhalers.
As part of Datamonitor Healthcare’s 2015 survey of 246 pulmonologists and primary care physicians across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), respondents were asked to consider how their prescribing behavior will change with the launch of new drug classes, including biologic therapies, once- and twice-daily long-acting beta 2 agonist/long-acting muscarinic antagonist therapies, as well as triple combination therapies.
Respondents were specifically asked to estimate the percentage of their diagnosed COPD patients of each severity that would be receiving a therapy belonging to the different drug classes and/or currently approved drugs, five years post-launch. The survey results (shown in the table below) indicate that while pulmonologists and primary care physicians are generally satisfied with the currently available therapies, they are keen to prescribe triple combination therapies to patients with severe and very severe COPD.
Future treatment in COPD, by severity (%)
|Mild COPD||Moderate COPD||Severe COPD||Very severe COPD|
|Triple FDC (ICS/LABA/LAMA) (with or without existing treatment)||5.04||14.48||35.62||42.11|
|All existing therapies||43.07||19.46||7.88||5.92|
|COPD = chronic obstructive pulmonary disease; FDC = fixed-dose combination; ICS = inhaled corticosteroid; LABA = long-acting beta 2 agonist; LAMA = long-acting muscarinic antagonist|
Source: Datamonitor Healthcare’s proprietary chronic obstructive pulmonary disease survey, April 2015
Datamonitor Healthcare’s COPD: Treatment provided a detailed analysis of COPD diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision-making and key treatment challenges.
Get your free demo today – simply fill out the form to the right.